Nektar Therapeutics
NKTR
$0.7955
$0.05487.40%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.22% | 5.53% | 6.17% | 1.51% | -2.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.22% | 5.53% | 6.17% | 1.51% | -2.10% |
| Cost of Revenue | -9.13% | -8.33% | 50.39% | 50.74% | 56.08% |
| Gross Profit | 20.21% | 13.69% | -11.70% | -16.08% | -19.97% |
| SG&A Expenses | -0.86% | -6.22% | -5.15% | -11.14% | -16.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.33% | -2.00% | -3.75% | -11.22% | -32.18% |
| Operating Income | 3.92% | 6.57% | 9.58% | 18.19% | 43.71% |
| Income Before Tax | 56.85% | 42.10% | 41.72% | 57.26% | 24.31% |
| Income Tax Expenses | -19.50% | -100.30% | -102.74% | -105.68% | -106.22% |
| Earnings from Continuing Operations | 56.91% | 42.69% | 42.30% | 57.61% | 25.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.91% | 42.69% | 42.30% | 57.61% | 25.03% |
| EBIT | 3.92% | 6.57% | 9.58% | 18.19% | 43.71% |
| EBITDA | 1.48% | 4.35% | 7.48% | 16.62% | 43.92% |
| EPS Basic | 60.01% | 46.09% | 44.63% | 58.36% | 26.08% |
| Normalized Basic EPS | 6.77% | 10.43% | 14.53% | 23.99% | 38.70% |
| EPS Diluted | 59.97% | 46.18% | 44.72% | 58.41% | 26.17% |
| Normalized Diluted EPS | 7.13% | 10.43% | 14.53% | 23.99% | 38.70% |
| Average Basic Shares Outstanding | 8.23% | 6.17% | 4.06% | 1.90% | 1.53% |
| Average Diluted Shares Outstanding | 8.74% | 6.17% | 4.06% | 1.90% | 1.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |